What question did this study set out to answer?

To evaluate treatment outcomes related to survival and quality of life among older adults with AML.

December 8, 2025Blood

Balancing the treatment outcomes: Survival and quality of life among older adults with AML

View Full Paper

Ask AI

Bookmark

Authors

Observational study finds azacitidine and venetoclax improve survival and quality of life in older adults with AML.

To evaluate treatment outcomes related to survival and quality of life among older adults with AML.
Prospective observational study conducted from July 2020 to April 2023.
Involved 190 older adults aged 60+ with newly diagnosed AML receiving either intensive or non-intensive treatment.
QOL measures assessed included FACT_Leu, MSAS, and BFI at multiple time points.
No significant treatment group differences in QOL at baseline.
At Day 30, fatigue was higher in non-intensive treatment group (42.3) than intensive (32.9), p=0.011.
Kaplan-Meier analysis showed median overall survival was 19.3 months for intensive and 9.1 months for non-intensive group, log-rank p=0.009.

Sallman et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark